IsoTis Files Definitive Proxy Statement
Special Stockholders Meeting to Approve Merger with Integra on October 11,
2007

IRVINE, CA, USA, - September 5, 2007 – IsoTis, Inc. (NASDAQ: ISOT)
(“IsoTis”), an orthobiologics company, today announced the filing of a
definitive proxy statement with the U.S. Securities and Exchange Commission
(“SEC”) in connection with the IsoTis-Integra LifeSciences Holdings
Corporation (NASDAQ: IART) (“Integra”) combination. The proxy statement is
available on the investor portion of the company’s corporate website, and
was first mailed to stockholders on or about September 5, 2007.

The Proxy Statement relates to a special meeting of stockholders of IsoTis
to be held on October 11, 2007 in Irvine, CA,, at which IsoTis’
stockholders will be asked to approve the acquisition of IsoTis by Integra
pursuant to an agreement and plan of merger dated as of August 6, 2007. If
the acquisition is consummated, stockholders will be entitled to receive
$7.25 in cash, without interest, for each share of IsoTis common stock that
they own.

IsoTis will also distribute to its stockholders a separate document that
highlights certain important components of the proxy statement and
translates these components into Dutch, French and German. These highlights
and translations will be mailed to stockholders and are made available on
the investor portion of the company’s corporate website.

In addition, in advance of the October 11, 2007 stockholder meeting, IsoTis
intends to hold information meetings for its European stockholders on the
following dates:

- September 25, 2007, 6 p.m., local time, at Hôtel Alpha-Palmiers,
located in Lausanne, Switzerland
- September 26, 2007, 6 p.m., local time, at Hotel Baur au Lac, located
in Zurich, Switzerland
- September 27, 2007, 6 p.m., local time, at World Trade Center
Schiphol Airport, located in Amsterdam, The Netherlands

The purpose of these meetings is to provide stockholders with an
opportunity to ask questions regarding the acquisition of IsoTis by
Integra. Stockholders will not be asked to vote on the transaction during
these information meetings. IsoTis stockholders will vote on the
transaction at the October 11, 2007 special meeting of stockholders to be
held in Irvine, California.

About IsoTis
IsoTis is an orthobiologics company that develops, manufactures and markets
proprietary products for the treatment of musculoskeletal diseases and
disorders. IsoTis’ current orthobiologics products are bone graft
substitutes that promote the regeneration of bone and are used to repair
natural, trauma-related and surgically-created defects common in orthopedic
procedures, including spinal fusions. IsoTis’ current commercial business
is highlighted by its Accell line of products, which the company believes
represents the next generation in bone graft substitution.

On August 7, 2007 Integra and IsoTis announced that they have reached a
definitive agreement to create a global orthobiologics leader. The
combination would create a comprehensive orthobiologics portfolio, one of
the largest sales organizations focused on orthobiologics in the US, and
multiple cross-selling opportunities. The transaction is subject to
approval of IsoTis' stockholders, as well as other closing conditions and
approvals. Upon closing, IsoTis will become a wholly-owned subsidiary of
Integra and Integra will be one of the largest companies in the world
focused on advanced technology in orthobiologics.